Skip to main content
. 2018 Nov 13;8:83–92. doi: 10.2147/PTT.S165943

Figure 1.

Figure 1

Summarized schematic differences between IL-12/23-p40, IL-23p19, and IL-17 blockade.

Notes: IL-12/23p40 inhibitors, such as ustekinumab, block IL-12 and IL-23 common subunit p40, inhibiting both IL-23/Th17 and IL-12/Th1 pathways; IL-23p19 inhibitors, such as risankizumab, guselkumab, and tildrakizumab, selectively block the IL-23/T17 pathway, avoiding effects on the IL-12/Th1 axis; IL-17A inhibitors, such as secukinumab and ixekizumab, also target the IL-23/IL-17 axis, although through downstream blockade of this pathway.

Abbreviations: DC, dendritic cell; INF-γ, interferon gamma; KC, keratinocyte; Th1 and Th17, T-helper cell 1 and 17; TNF-α, tumor necrosis factor alpha.